University Hospitals Case Medical Center
Cleveland, Ohio, 44106, United States
NCT Number: NCT02127814
The purpose of this study is to find whether Lactobacillus reuteri prevents antibiotic-associated diarrhea and related Clostridium difficile infections. Subjects will be admitted from the University Hospitals Case Medical Center. They will be randomly assigned to an intervention group receiving L. reuteri or a placebo. Supplementation will occur during antibiotic treatment and for an additional 7 days after cessation of treatment. Data collection will occur at baseline, end of antibiotic use, 7 days after antibiotic cessation, and 21 days after antibiotic cessation. Primary data includes diarrhea instances. Secondary data includes severity of diarrhea, presence of C. difficile toxins, and presence of other GI symptoms.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Cleveland, Ohio, 44106, United States
The data being measured for this study include:
Primary outcome = incidence of diarrhea during and after treatment with antibiotics. An episode of diarrhea is defined as the discrete period between the time when stool output meets or exceeds three soft and unformed or watery bowel movements to the time when formed stools return, which must be at least 48 hours later.
Secondary variables:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One chewable tablet of 1E8 CFU L. reuteri, once per day
Other names: BioGaia, Probiotic Chewable Tablets
Time frame: 28+ days
Instances of diarrhea
Time frame: 28+ days
measured as the discrete period between the time when stool output meets or exceeds three soft and unformed or watery bowel movements to the time when formed stools return.
Time frame: baseline, when presenting with diarrhea during the study period, and at the follow-up 21 days
Frequency of stool samples positive for C. difficile toxin A and B at baseline, when presenting with diarrhea during the study period, and at the follow-up 21 days post antibiotic-treatment to detect possible clearance of C. difficile, in patients ingesting L. reuteri versus placebo.
Time frame: 1, 2 and 4 weeks
Frequencies of other gastrointestinal symptoms at 1, 2 and 4 weeks, in the L. reuteri group versus placebo and assessed by the validated GSRS score (Gastrointestinal Symptom Rating Score).
Case Western Reserve University
Other
Efficacy and Safety of the Probiotic Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile Related Infections in Hospitalized Adult Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07234448
Antibiotic-associated Diarrhea
Urbino, Italy
View Trial DetailsNCT05845073
Antibiotic-associated Diarrhea
Berlin, Weißenseer Weg, Germany
View Trial DetailsNCT04414722
Antibiotic-associated Diarrhea
Washington D.C., District of Columbia, United States
View Trial DetailsNCT03181516
Antibiotic-associated Diarrhea
Washington D.C., District of Columbia, United States
View Trial Details